Trial Profile
A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Nov 2019 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Aug 2016 Planned End Date changed from 1 Apr 2014 to 1 Dec 2016.
- 02 Aug 2016 Planned primary completion date changed from 1 Apr 2014 to 1 Dec 2016.